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LETTERS TO THE EDITOR
Is the Tolerability of Long-Term
Thiazolidinedione Therapy Overstated?
The study by Tang et al. (1) concluded that their retrospective
chart review demonstrated the tolerability of long-term thiazo-
lidinedione (TZD) therapy in a diabetic population with estab-
lished chronic heart failure (HF). Although we applaud their
efforts to study this important topic, we believe the data presented
are not so clear, and that their conclusions that a large majority of
chronic HF patients tolerate these agents are overstated.
First, we believe the definition of TZD-related fluid retention,
as a 10-pound weight gain from baseline, in addition to signs or
symptoms of volume overload, is far too exclusive of important levels
of fluid retention. By using this cut-off, we can be sure that those
patients had severe fluid retention. However, we do not know the
number of other patients who had important levels of weight gain or
edema and who were missed by the investigators’ likely insensitive
criteria. Heart failure guidelines recommend action when weight
increases by 2 to 4 pounds depending on how quickly it occurs.
Second, we disagree that the reported incidence of fluid reten-
tion of 17.1% is an overestimate due to selection bias. In fact, it is
probably an underestimate. Obtaining data from a chart review can
only lead to under-reporting the true incidence of fluid retention
and adverse events. Furthermore, the majority of patients had
stable New York Heart Association functional class I or II heart
failure where TZD therapy is not contraindicated. (The incidence
of edema [with or without weight gain] in TZD randomized
controlled trials ranged between 2% and 15% [2,3].)
Third, the intolerability of these agents in this population is
further illustrated by the fact that 31% discontinued TZD therapy
within one year of initiation (most due to fluid retention), whereas
the rate of discontinuation was far 0.1% in randomized con-
trolled trials (2,3). Also of concern is that 26% of patients who met
the criteria for fluid retention were hospitalized. Finally, we are
concerned that both the data and the discussion regarding the
incidence of fluid retention and characteristics of the non-TZD
control group were very limited. This data would likely provide
more insight into the true tolerability of these medications in this
population.
In summary, we agree that further studies are needed to
examine the relationship between TZD-related fluid retention and
patient cardiac status. We believe this study and its conclusions
should be interpreted very carefully, as the true risks of adverse
effects related to volume expansion are likely understated.
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REPLY
We appreciate the comments by Dr. Malone and his colleagues
regarding our recent report on the characteristics of fluid retention
after initiation of thiazolidinedione (TZD) therapy in diabetic
patients with established chronic heart failure (HF). In our report,
we fully acknowledged that fluid retention does occur with TZD
use in patients with established HF, and until we have more
experience with this drug class “there is little doubt that
TZDs. . .should be avoided in highly symptomatic patients with
HF who are already having difficulty maintaining a balanced
volume status” (1). Although we recognize that the definition of
fluid retention is arbitrary, there is currently no gold standard for
“important levels of fluid retention.” We chose the 10-pound limit
to account for the long-term, nonedematous weight gain associ-
ated with TZD use that has been previously reported in the
literature (2). It is noteworthy that 68% of patients received 12
months of TZD therapy without demonstrating significant fluid
retention. Also, 20% of patients in our cohort had TZD discon-
tinued owing to reasons other than edema. Until we have more
objective measures to quantify the degree of fluid retention (such as
sequential plasma volume analyses or surrogate markers like plasma
B-type natriuretic peptide levels), observations of this nature can
only rely on “insensitive” clinical criteria.
The selection bias in this retrospective observational study
originated from the referral nature of the specialized HF clinic,
where a large number of patients are seen specifically because of
fluid retention following TZD initiation. Meanwhile, the non-
TZD user “control” group in our study was used in a nested
case-controlled manner to illustrate the discrepancy in clinical
presentation between TZD-related fluid retention and what we
commonly consider to be HF exacerbation independent of TZD
use. As stated in our discussion, the incomplete nature of retro-
spective data collection precludes any statistical comparisons be-
tween groups (including drug tolerability) so as to avoid false
inferences. Although we agree that any association between TZD-
related fluid retention and patient’s cardiac status should be
interpreted with caution, we argue against the proscription of this
drug class in patients with HF simply by equating fluid retention
with HF exacerbation. What is more alarming to us is the paucity
of published reports in this area (limited to sporadic case reports)
over the past few years despite widespread recognition of the
metabolic syndrome and the potential benefits of this class of drugs
in such patients. The true incidence of TZD-related fluid reten-
tion and TZD tolerability in patients with HF can only be
determined by well-designed prospective studies specifically ad-
dressing patients with HF.
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